Rival permanent heart implants enter human trials
This article was originally published in Clinica
Executive Summary
US company Arrow International last week announced the first clinical implant of its permanent heart replacement device for patients with end-stage heart failure. At the same time, its competitor Abiomed said that it was ready to start human trials of its permanent device, assuming it gets regulatory approval, now that it is producing clinically configured versions of the AbioCor pump.